Cargando…

Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy

Background: Anthracycline (ANT) is the most recognized therapy known to cause cardiotoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent...

Descripción completa

Detalles Bibliográficos
Autores principales: Laufer-Perl, Michal, Perelman-Gvili, Moran, Sirota Dorfman, Svetlana, Baruch, Guy, Rothschild, Ehud, Beer, Gil, Arbel, Yaron, Arnold, Joshua H., Rozenbaum, Zach, Banai, Shmuel, Topilsky, Yan, Kapusta, Livia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877607/
https://www.ncbi.nlm.nih.gov/pubmed/35207578
http://dx.doi.org/10.3390/life12020291
_version_ 1784658460247326720
author Laufer-Perl, Michal
Perelman-Gvili, Moran
Sirota Dorfman, Svetlana
Baruch, Guy
Rothschild, Ehud
Beer, Gil
Arbel, Yaron
Arnold, Joshua H.
Rozenbaum, Zach
Banai, Shmuel
Topilsky, Yan
Kapusta, Livia
author_facet Laufer-Perl, Michal
Perelman-Gvili, Moran
Sirota Dorfman, Svetlana
Baruch, Guy
Rothschild, Ehud
Beer, Gil
Arbel, Yaron
Arnold, Joshua H.
Rozenbaum, Zach
Banai, Shmuel
Topilsky, Yan
Kapusta, Livia
author_sort Laufer-Perl, Michal
collection PubMed
description Background: Anthracycline (ANT) is the most recognized therapy known to cause cardiotoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent factor for cardiac outcomes; however, data evaluating RV GLS is limited. We aimed to evaluate the change in RV GLS following ANT therapy. Methods: The study cohort is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed echocardiography before (T1) and at the end (T3) of ANT therapy. A significant reduction was defined as a relative reduction of ≥10% in RV GLS values. Results: The study included 40 female patients with breast cancer treated with ANT. During follow-up, both RV GLS and free wall longitudinal strain systolic peak (RV FWLS PK) decreased significantly (p < 0.001 and p = 0.002). Altogether, 30 (75%) and 23 (58%) patients showed RV GLS and RV FWLS PK ≥ 10% relative reduction. At T3, LV ejection fraction and LV GLS were within normal range. Conclusions: RV GLS and RV FWLS PK reduction following ANT exposure is extremely frequent, comparing to LV GLS reduction.
format Online
Article
Text
id pubmed-8877607
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88776072022-02-26 Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy Laufer-Perl, Michal Perelman-Gvili, Moran Sirota Dorfman, Svetlana Baruch, Guy Rothschild, Ehud Beer, Gil Arbel, Yaron Arnold, Joshua H. Rozenbaum, Zach Banai, Shmuel Topilsky, Yan Kapusta, Livia Life (Basel) Article Background: Anthracycline (ANT) is the most recognized therapy known to cause cardiotoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent factor for cardiac outcomes; however, data evaluating RV GLS is limited. We aimed to evaluate the change in RV GLS following ANT therapy. Methods: The study cohort is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed echocardiography before (T1) and at the end (T3) of ANT therapy. A significant reduction was defined as a relative reduction of ≥10% in RV GLS values. Results: The study included 40 female patients with breast cancer treated with ANT. During follow-up, both RV GLS and free wall longitudinal strain systolic peak (RV FWLS PK) decreased significantly (p < 0.001 and p = 0.002). Altogether, 30 (75%) and 23 (58%) patients showed RV GLS and RV FWLS PK ≥ 10% relative reduction. At T3, LV ejection fraction and LV GLS were within normal range. Conclusions: RV GLS and RV FWLS PK reduction following ANT exposure is extremely frequent, comparing to LV GLS reduction. MDPI 2022-02-15 /pmc/articles/PMC8877607/ /pubmed/35207578 http://dx.doi.org/10.3390/life12020291 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Laufer-Perl, Michal
Perelman-Gvili, Moran
Sirota Dorfman, Svetlana
Baruch, Guy
Rothschild, Ehud
Beer, Gil
Arbel, Yaron
Arnold, Joshua H.
Rozenbaum, Zach
Banai, Shmuel
Topilsky, Yan
Kapusta, Livia
Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy
title Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy
title_full Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy
title_fullStr Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy
title_full_unstemmed Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy
title_short Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy
title_sort prevalence of right ventricle strain changes following anthracycline therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877607/
https://www.ncbi.nlm.nih.gov/pubmed/35207578
http://dx.doi.org/10.3390/life12020291
work_keys_str_mv AT lauferperlmichal prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT perelmangvilimoran prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT sirotadorfmansvetlana prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT baruchguy prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT rothschildehud prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT beergil prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT arbelyaron prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT arnoldjoshuah prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT rozenbaumzach prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT banaishmuel prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT topilskyyan prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy
AT kapustalivia prevalenceofrightventriclestrainchangesfollowinganthracyclinetherapy